Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

FDA

  • Home
  •  
  • FDA



  • Most Read
  • Latest Comments
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Lumos Diagnostics expands FebriDx distribution to Belgium
    Lumos Diagnostics expands FebriDx distribution to Belgium
    • News

  • Lumos completes phase 1 of developing premature birth detection test
    Lumos completes phase 1 of developing premature birth detection test
    • News

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    • News

  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits

    While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits.  As a rapid diagnostic test that

    Read More
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    Why one contentious FDA drug approval is good news for Actinogen Medical

    Whether you’re running for the train, or running from a lion, cortisol- the stress hormone, plays an important role in making sure you aren’t late, or eaten.  Except, too much cortisol has detrimental effects to the brain and our health, with research suggesting that cortisol dysregulation can affect cognitive function and harm brain cells in

    Read More
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • News

    Uh oh…People: A new approach to treating Social Anxiety Disorder

    If the festive season has left you feeling depleted and ready for a solid few nights in, cemented to the couch, you’re not alone. Social interactions can be draining at the best of times for my fellow introverts, but it’s even tougher for those with Social Anxiety Disorder.  According to the Diagnostic and Statistical Manual

    Read More
    Public
  • Will this drug be the solution to social anxiety issues of upcoming generations?
    • News

    Will this drug be the solution to social anxiety issues of upcoming generations?

    Where kids of yesteryear might have been labelled shy due to hesitations in social situations, coming generations of children will be classified as having Social Anxiety Disorder as a result of hypervigilant parenting in the digital age. While some will be self-treated via social experimentation, others will struggle without medical intervention which is just one

    Read More
    Public
  • FDA gives green light to Pharmaxis drug trial in liver cancer where there’s a desperate need for new treatments
    • News

    FDA gives green light to Pharmaxis drug trial in liver cancer where there’s a desperate need for new treatments

    Clinical stage drug development company, Pharmaxis (ASX: PXS) is making a name for themselves in the oncology sector, with their lead asset oncology drug yielding promising results in numerous studies.  PXS-5505, a drug designed for the treatment of rare blood cancer myelofibrosis is built on Pharmaxis’ proprietary platform, harnessing the power of enzyme inhibition to

    Read More
    Public
  • Tackling heart attacks with world first implantable monitoring device
    • News

    Tackling heart attacks with world first implantable monitoring device

    A heart attack can feel like literally anything. A sore arm, jaw pain, nausea… The list goes on. Difficulty in recognising a heart attack due to atypical symptoms increases for women, elderly and diabetics. The wide scope of symptoms can often result in costly emergency room visits and tests just to discover simple indigestion is

    Read More
    Public
  • 1
  • 2
  • 3
  • 4

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.